Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Integrin-Linked Kinase a Novel Therapeutic Target for Acute and Chronic Myeloid Leukemia

Pilar De La Puente, PhD, Ellen Weisberg, MD, Atsushi Nonami, MDPhD, Micah John Luderer, BS, MS, Richard M. Stone, MD, Junia V. Melo, MD PhD, James D Griffin, MD, Abdel Kareem Azab, BPharm, PhD

Blood (2015) 126 (23): 3694.

https://doi.org/10.1182/blood.V126.23.3694.3694

Published: 2015

Journal Articles

Transfusion Dependency Is Associated With Inferior Survival Even In Very Low and Low Risk IPSS-R Patients

Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Monika M Kutyna, Rakchha Chhetri, Stuart Howell, Peter B Harrison, Shriram V Nath, Lakshmi S Nath, Nicholas Wickham, Ferenc Szabo, Chi-Hung Hui, David Ross, James Gray, Junia V Melo, MD, PhD, Peter Bardy, L. Bik To

Blood (2013) 122 (21): 1518.

https://doi.org/10.1182/blood.V122.21.1518.1518

Published: 2013

Journal Articles

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

David M. Ross, Susan Branford, John F. Seymour, Anthony P. Schwarer, Christopher Arthur, David T. Yeung, Phuong Dang, Jarrad M. Goyne, Cassandra Slader, Robin J. Filshie, Anthony K. Mills, Junia V. Melo, Deborah L. White, Andrew P. Grigg, Timothy P. Hughes

Blood (2013) 122 (4): 515–522.

https://doi.org/10.1182/blood-2013-02-483750

Published: 2013

Includes: Supplemental data

Journal Articles

BCR-ABL-Induced Downregulation of GADD45G in Chronic Myeloid Leukemia

Debora A Casolari, PhD, Jun Ishiko, MD, PhD, Michelle Perugini, PhD, Richard J D'Andrea, PhD, Junia V Melo, MD, PhD

Blood (2012) 120 (21): 3731.

https://doi.org/10.1182/blood.V120.21.3731.3731

Published: 2012

Journal Articles

Socs2 Is Dispensable for BCR/ABL1-Induced Chronic Myeloid Leukemia-Like Disease in Mice and for Normal Hematopoietic Stem Cell Function,

Nils Hansen, Helena Agerstam, PhD, Martin Wahlestedt, Mats Ehinger, MD, PhD, Petra Johnels, PhD, Jun Ishiko, PhD, Junia V. Melo, MD, PhD, Warren S Alexander, PhD, David Bryder, Marcus Järås, PhD, Thoas Fioretos, MD, PhD

Blood (2011) 118 (21): 3743.

https://doi.org/10.1182/blood.V118.21.3743.3743

Published: 2011

Journal Articles

Mechanisms of Co-Operation of DNMT3A Mutations with JAK2 V617F Through Histone H4 Arginine 3 Provides New Insights in MPN Disease Pathogenesis

Nisha Rao, Carolyn M Butcher, MMedSc(Hon), Petra J Neufing, Sarah Bray, Chris N Hahn, Hamish S Scott, PhD, Junia V. Melo, MD, PhD, David Ross, MBBS, PhD, Ian D Lewis, MBBS, PhD, Peter Bardy, MD, Richard J D'Andrea, PhD

Blood (2011) 118 (21): 2823.

https://doi.org/10.1182/blood.V118.21.2823.2823

Published: 2011

Journal Articles

SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome–positive cells derived from patients with chronic myeloid leukemia

Blood (2011) 118 (13): 3634–3644.

https://doi.org/10.1182/blood-2011-03-341073

Published: 2011

Includes: Supplemental data

Journal Articles

Wrapping BCR-ABL: it's in the bag

Junia V. Melo, Duncan R. Hewett

Blood (2010) 116 (18): 3382–3383.

https://doi.org/10.1182/blood-2010-08-300608

Published: 2010

Journal Articles

In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib

Manuel Sobrinho-Simões, Vicki Wilczek, Joannah Score, Nicholas C. P. Cross, Jane F. Apperley, Junia V. Melo

Blood (2010) 116 (8): 1329–1335.

https://doi.org/10.1182/blood-2009-11-255109

Published: 2010

Includes: Supplemental data

Journal Articles

Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants

Blood (2010) 115 (21): 4206–4216.

https://doi.org/10.1182/blood-2009-11-251751

Published: 2010

Includes: Supplemental data

Journal Articles

A gene expression signature of CD34 + cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib

Shannon K. McWeeney, Lucy C. Pemberton, Marc M. Loriaux, Kristina Vartanian, Stephanie G. Willis, Gregory Yochum, Beth Wilmot, Yaron Turpaz, Raji Pillai, Brian J. Druker, Jennifer L. Snead, Mary MacPartlin, Stephen G. O'Brien, Junia V. Melo, Thoralf Lange, Christina A. Harrington, Michael W. N. Deininger

Blood (2010) 115 (2): 315–325.

https://doi.org/10.1182/blood-2009-03-210732

Published: 2010

Includes: Supplemental data

Journal Articles

Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?

Susan Branford, Junia V. Melo, Timothy P. Hughes

Blood (2009) 114 (27): 5426–5435.

https://doi.org/10.1182/blood-2009-08-215939

Published: 2009

Journal Articles

Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells.

Devendra K Hiwase, MD, Deborah L White, PhD, Jason A Powell, PhD, Verity A Saunders, Stephanie Zrim, Amity Frede, Mark Guthridge, Richard D'Andrea, PhD, L. Bik To, MD, Junia V. Melo, MD, PhD, Sharad Kumar, PhD, Timothy Hughes, MD

Blood (2009) 114 (22): 3250.

https://doi.org/10.1182/blood.V114.22.3250.3250

Published: 2009

Journal Articles

Targeting Isoprenylcysteine Carboxyl Methyltransferase to Overcome Resistance and Improve Responses in Chronic Myeloid Leukemia.

Wen Tian Sun, PhD, Bee Ling Ng, PhD, Li Yi Yang, BSc, Mei Wang, MD, PhD, William Hwang, MBBS, FRCP, Junia V. Melo, MD, PhD, Brian J. Druker, MD, Patrick J Casey, PhD, Charles Chuah, MBChB, MRCP, MD

Blood (2009) 114 (22): 3273.

https://doi.org/10.1182/blood.V114.22.3273.3273

Published: 2009

Journal Articles

A Gene Expression Signature of CD34+ Cells to Predict Major Cytogenetic Response in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib: Potential Involvement of Beta-Catenin in Drug Resistance.

Shannon McWeeney, Gregory Yochum, Lucy C. Pemberton, MD, FRCPath, Marc Loriaux, MD, PhD, Kristina Vartanian, Stephanie G Willis, Beth Wilmot, Yaron Turpaz, Raji Pillai, Mary Mac partlin, Jennifer Snead, PhD, Brian J. Druker, MD, Stephen G O'Brien, MD, PhD, Junia V. Melo, MD, PhD, Thoralf Lange, MD, Christina Harrington, Michael Deininger, MD, PhD

Blood (2009) 114 (22): 508.

https://doi.org/10.1182/blood.V114.22.508.508

Published: 2009

Journal Articles

Bcr-Abl Positive Cells Display Increased Proteasome Activity and Greater Sensitivity to Proteasome Inhibition

Lisa Crawford, PhD, BSc, Philip Windrum, MD, MRCPath, Laura Magill, PhD, BSc, Junia V. Melo, MD, PhD, FRCPath, Lynn McCallum, PhD, BSc, MaryFrances McMullin, MD, Huib Ovaa, PhD, BSc, Brian Walker, PhD, BSc, Alexandra Irvine, PhD

Blood (2008) 112 (11): 3192.

https://doi.org/10.1182/blood.V112.11.3192.3192

Published: 2008

Journal Articles

Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Acute Lymphoblastic Leukemia (ALL).

Renata A. Meyer, MD, Harald Herrmann, MD, Karoline V. Gleixner, MD, Alexander Gruze, Sabine Cerny-Reiterer, MD, Rainer Hubmann, PhD, Medhat Shehata, MD, Matthias Mayerhofer, MD, Wolfgang R. Sperr, MD, Winfried F. Pickl, MD, Junia V. Melo, PhD, Gahininath Y. Bharate, Ulrich Jäger, MD, Hiroshi Maeda, MD, PhD, Peter Valent, MD

Blood (2008) 112 (11): 1616.

https://doi.org/10.1182/blood.V112.11.1616.1616

Published: 2008

Journal Articles

Short –Term Intense Bcr-Abl Kinase Inhibition Is Adequate to Trigger Cell Death in CML Cell Lines but Not in CML-CD34+ Cells Unless They Are Growth Factor Deprived.

Devendra K. Hi Wase, MD, Deborah L. White, PhD, Verity A. Saunders, Junia V. Melo, MD, PhD, Sharad Kumar, PhD, Timothy P. Hughes, MD

Blood (2008) 112 (11): 1086.

https://doi.org/10.1182/blood.V112.11.1086.1086

Published: 2008

Journal Articles

Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia

Mohamad Mohty, Richard M. Szydlo, Agnes S. M. Yong, Jane F. Apperley, John M. Goldman, Junia V. Melo

Blood (2008) 112 (5): 2163–2166.

https://doi.org/10.1182/blood-2008-04-148130

Published: 2008

Journal Articles

HOX Genes - Candidate Tumor Suppressor Genes in Adult and Childhood Leukemia.

Gordon R. Strathdee, Tessa L. Holyoake, Alyson Sim, Anton Parker, David G. Oscier, Junia V. Melo, Stefan Meyer, Tim Eden, Anne M. Dickinson, Joanne Mountford, Heather G. Jorgensen, Richard Soutar, Robert Brown

Blood (2007) 110 (11): 2641.

https://doi.org/10.1182/blood.V110.11.2641.2641

Published: 2007

NARROW

Integrin-Linked Kinase a Novel Therapeutic Target for Acute and Chronic Myeloid Leukemia

Transfusion Dependency Is Associated With Inferior Survival Even In Very Low and Low Risk IPSS-R Patients

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

BCR-ABL-Induced Downregulation of GADD45G in Chronic Myeloid Leukemia

Socs2 Is Dispensable for BCR/ABL1-Induced Chronic Myeloid Leukemia-Like Disease in Mice and for Normal Hematopoietic Stem Cell Function,

Mechanisms of Co-Operation of DNMT3A Mutations with JAK2 V617F Through Histone H4 Arginine 3 Provides New Insights in MPN Disease Pathogenesis

SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome–positive cells derived from patients with chronic myeloid leukemia

Wrapping BCR-ABL: it's in the bag

In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib

Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants

A gene expression signature of CD34 + cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib

Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?

Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells.

Targeting Isoprenylcysteine Carboxyl Methyltransferase to Overcome Resistance and Improve Responses in Chronic Myeloid Leukemia.

A Gene Expression Signature of CD34+ Cells to Predict Major Cytogenetic Response in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib: Potential Involvement of Beta-Catenin in Drug Resistance.

Bcr-Abl Positive Cells Display Increased Proteasome Activity and Greater Sensitivity to Proteasome Inhibition

Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Acute Lymphoblastic Leukemia (ALL).

Short –Term Intense Bcr-Abl Kinase Inhibition Is Adequate to Trigger Cell Death in CML Cell Lines but Not in CML-CD34+ Cells Unless They Are Growth Factor Deprived.

Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia

HOX Genes - Candidate Tumor Suppressor Genes in Adult and Childhood Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only